An Open-Label Trial of Riluzole in Patients with Treatment-Resistant Major Depression

Carlos A. Zarate, Jennifer Payne, Jorge Quiroz, Jonathan Sporn, Kirk K. Denicoff, David Luckenbaugh, Dennis S. Charney, Husseini K. Manji

Research output: Contribution to journalArticle

Abstract

Objective: This study was conducted to determine the efficacy and safety of riluzole, a glutamate-modulating agent, in patients with recurrent major depression. Method: After a 1-week drug-free period, subjects 18 years or older with a diagnosis of recurrent major depression and a Montgomery-Asberg Depression Rating Scale score ≥20 received riluzole monotherapy (100-200 mg/day) openly for 6 weeks. Results: Nineteen treatment-resistant depressed patients, 53% of whom were classified as having stage 2 treatment resistance or greater, received riluzole at a mean dose of 169 mg/day. Significant improvement occurred during weeks 3 through 6 for all patients and weeks 2 through 6 for completers. Conclusions: Although preliminary these results indicate that riluzole may have antidepressant properties in some patients.

Original languageEnglish (US)
Pages (from-to)171-174
Number of pages4
JournalAmerican Journal of Psychiatry
Volume161
Issue number1
DOIs
StatePublished - Jan 2004
Externally publishedYes

Fingerprint

Riluzole
Treatment-Resistant Depressive Disorder
Depression
Excitatory Amino Acid Agents
Antidepressive Agents
Safety
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Zarate, C. A., Payne, J., Quiroz, J., Sporn, J., Denicoff, K. K., Luckenbaugh, D., ... Manji, H. K. (2004). An Open-Label Trial of Riluzole in Patients with Treatment-Resistant Major Depression. American Journal of Psychiatry, 161(1), 171-174. https://doi.org/10.1176/appi.ajp.161.1.171

An Open-Label Trial of Riluzole in Patients with Treatment-Resistant Major Depression. / Zarate, Carlos A.; Payne, Jennifer; Quiroz, Jorge; Sporn, Jonathan; Denicoff, Kirk K.; Luckenbaugh, David; Charney, Dennis S.; Manji, Husseini K.

In: American Journal of Psychiatry, Vol. 161, No. 1, 01.2004, p. 171-174.

Research output: Contribution to journalArticle

Zarate, CA, Payne, J, Quiroz, J, Sporn, J, Denicoff, KK, Luckenbaugh, D, Charney, DS & Manji, HK 2004, 'An Open-Label Trial of Riluzole in Patients with Treatment-Resistant Major Depression', American Journal of Psychiatry, vol. 161, no. 1, pp. 171-174. https://doi.org/10.1176/appi.ajp.161.1.171
Zarate, Carlos A. ; Payne, Jennifer ; Quiroz, Jorge ; Sporn, Jonathan ; Denicoff, Kirk K. ; Luckenbaugh, David ; Charney, Dennis S. ; Manji, Husseini K. / An Open-Label Trial of Riluzole in Patients with Treatment-Resistant Major Depression. In: American Journal of Psychiatry. 2004 ; Vol. 161, No. 1. pp. 171-174.
@article{83ded4fb77f84c078b12b00da5dc71d4,
title = "An Open-Label Trial of Riluzole in Patients with Treatment-Resistant Major Depression",
abstract = "Objective: This study was conducted to determine the efficacy and safety of riluzole, a glutamate-modulating agent, in patients with recurrent major depression. Method: After a 1-week drug-free period, subjects 18 years or older with a diagnosis of recurrent major depression and a Montgomery-Asberg Depression Rating Scale score ≥20 received riluzole monotherapy (100-200 mg/day) openly for 6 weeks. Results: Nineteen treatment-resistant depressed patients, 53{\%} of whom were classified as having stage 2 treatment resistance or greater, received riluzole at a mean dose of 169 mg/day. Significant improvement occurred during weeks 3 through 6 for all patients and weeks 2 through 6 for completers. Conclusions: Although preliminary these results indicate that riluzole may have antidepressant properties in some patients.",
author = "Zarate, {Carlos A.} and Jennifer Payne and Jorge Quiroz and Jonathan Sporn and Denicoff, {Kirk K.} and David Luckenbaugh and Charney, {Dennis S.} and Manji, {Husseini K.}",
year = "2004",
month = "1",
doi = "10.1176/appi.ajp.161.1.171",
language = "English (US)",
volume = "161",
pages = "171--174",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "1",

}

TY - JOUR

T1 - An Open-Label Trial of Riluzole in Patients with Treatment-Resistant Major Depression

AU - Zarate, Carlos A.

AU - Payne, Jennifer

AU - Quiroz, Jorge

AU - Sporn, Jonathan

AU - Denicoff, Kirk K.

AU - Luckenbaugh, David

AU - Charney, Dennis S.

AU - Manji, Husseini K.

PY - 2004/1

Y1 - 2004/1

N2 - Objective: This study was conducted to determine the efficacy and safety of riluzole, a glutamate-modulating agent, in patients with recurrent major depression. Method: After a 1-week drug-free period, subjects 18 years or older with a diagnosis of recurrent major depression and a Montgomery-Asberg Depression Rating Scale score ≥20 received riluzole monotherapy (100-200 mg/day) openly for 6 weeks. Results: Nineteen treatment-resistant depressed patients, 53% of whom were classified as having stage 2 treatment resistance or greater, received riluzole at a mean dose of 169 mg/day. Significant improvement occurred during weeks 3 through 6 for all patients and weeks 2 through 6 for completers. Conclusions: Although preliminary these results indicate that riluzole may have antidepressant properties in some patients.

AB - Objective: This study was conducted to determine the efficacy and safety of riluzole, a glutamate-modulating agent, in patients with recurrent major depression. Method: After a 1-week drug-free period, subjects 18 years or older with a diagnosis of recurrent major depression and a Montgomery-Asberg Depression Rating Scale score ≥20 received riluzole monotherapy (100-200 mg/day) openly for 6 weeks. Results: Nineteen treatment-resistant depressed patients, 53% of whom were classified as having stage 2 treatment resistance or greater, received riluzole at a mean dose of 169 mg/day. Significant improvement occurred during weeks 3 through 6 for all patients and weeks 2 through 6 for completers. Conclusions: Although preliminary these results indicate that riluzole may have antidepressant properties in some patients.

UR - http://www.scopus.com/inward/record.url?scp=1442264398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1442264398&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.161.1.171

DO - 10.1176/appi.ajp.161.1.171

M3 - Article

VL - 161

SP - 171

EP - 174

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 1

ER -